PYC THERAPEUTICS LIMITED (ASX: PYC)
Health care · News and insights
Price unavailable
Latest PYC announcements
Announcement Insights
PYC Meets Kidney-Trial Enrolment Target, With Key Data Still Due in 2027
PYC Therapeutics has met the interim target of enrolling 24 patients in the repeat-dose PYC-003 study for polycystic kidney disease, advancing toward its planned 2027 data readouts. The company had already said in October that kidney-study data was expected in 2027; the latest update specifies 12-month kidney-volume data from at least 24 patients, alongside results from repeat-dose and extension studies. A potential Phase 2/3 trial in 2028 remains subject to regulatory alignment and other conditions.
Updated 13 Nov 2026, 08:52 AM Sydney time
Sources
PKD Program - Enrolment Target Met2026 Annual General Meeting Program and CEO PresentationResults of Annual General MeetingNotification regarding unquoted securities - PYCAnnual General Meeting - Conference LinkChange of Director's Interest NoticeChange of Director's Interest NoticeApplication for quotation of securities - PYCExercise of Options and Cleansing NoticeChange of Director's Interest NoticeQuarterly Activities/Appendix 4C Cash Flow ReportComments
2026-11-13 · Health care
PYC: $1.84 -4.18% · MC: $1.9B
PYC Therapeutics has met its interim enrolment target of 24 patients in the Phase 1b repeat-dose study of PYC-003 for polycystic kidney disease and will continue recruiting. The company aims to report kidney volume data for at least 24 patients in calendar 2027 and progress to a potentially registrational Phase 2/3 trial in 2028, subject to regulatory alignment and patient dropout assumptions. It also expects to present data from the ongoing study and its open-label extension in 2027.
Updated 2026-11-13 11:01
Sources
PKD Program - Enrolment Target MetComments
2026-11-12 · Health care
PYC: $1.91 +0.52% · MC: $1.9B
PYC Therapeutics shareholders passed all resolutions at the 2026 AGM, including awards of restricted and performance rights to CEO Rohan Hockings, which received strong support. Approval for up to 1.5 million options for Hockings drew more opposition, with about 28% of votes cast against; options for Professor Ian Constable received about 35% opposition.
Updated 2026-11-12 13:31
Sources
2026 Annual General Meeting Program and CEO PresentationResults of Annual General MeetingComments
2026-11-09 · Health care
PYC: $1.99 +5.85% · MC: $1.9B
PYC Therapeutics issued service rights under its employee incentive scheme, increasing the total number of unquoted service rights on issue. The rights are divided into three tranches with measurement periods running from November 2026 to November 2029.
Updated 2026-11-09 16:48
Sources
Notification regarding unquoted securities - PYCComments
2026-11-05 · Health care
PYC: $1.93 +4.32% · MC: $1.9B
PYC Therapeutics director Ian Constable bought shares on market through a family trust, increasing his indirect holding by about 16%. The purchase follows separate on-market acquisitions by directors Rohan Hockings and Peter Coleman in recent days. PYC also reminded shareholders that its AGM will be held next Thursday in Nedlands, Western Australia, with a Zoom option available through advance registration.
Updated 2026-11-05 16:23
Sources
Annual General Meeting - Conference LinkChange of Director's Interest NoticeComments
2026-11-03 · Health care
PYC: $1.80 -5.26% · MC: $1.9B
PYC Therapeutics director Rohan Hockings bought shares on market for approximately $206,000, increasing his direct ordinary shareholding by nearly 39%. The purchase follows director Peter Coleman's on-market acquisition of shares for approximately $202,000 last week. Hockings is also due to receive options and restricted rights under incentive plans, subject to shareholder approval.
Updated 2026-11-03 16:12
Sources
Change of Director's Interest NoticeComments
2026-10-30 · Health care
PYC: $1.88 -2.84% · MC: $1.9B
PYC issued shares after holders exercised options, while director Peter Coleman disclosed an indirect on-market acquisition of shares through a trust. The company issued 540,000 shares at $1.70 each, and Coleman’s disclosed purchase was valued at approximately $202,000.
Updated 2026-10-30 16:30
Sources
Exercise of Options and Cleansing NoticeApplication for quotation of securities - PYCChange of Director's Interest NoticeComments
2026-10-29 · Health care
PYC: $1.93 -1.78% · MC: $1.9B
PYC Therapeutics reported progress across four drug programs, including advancing its Phelan-McDermid candidate into required toxicology studies and moving its kidney-disease candidate into higher-dose and longer-term studies. The company said data from the ongoing kidney studies is expected in 2027, while early exploratory results from a single-dose study were presented after the quarter.
Updated 2026-10-29 08:45
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
Comments